VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
Saved in:
| Title: | VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML. |
|---|---|
| Authors: | Kretschmer L; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany. lydia.kretschmer@ukdd.de., Ruhnke L; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany., Fransecky L; Department of Hematology and Oncology, University Hospital Schleswig- Holstein, Campus Kiel, Kiel, Germany., Steffen B; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Kaufmann M; Robert Bosch Hospital, Stuttgart, Germany., Burchert A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Schmid C; Department of Internal Medicine II, Hematology and Oncology, University Hospital Augsburg, Augsburg, Germany., Hanoun M; Department of Hematology and Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Sauer T; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Metzeler KH; Department of Internal Medicine I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany., Schäfer-Eckart K; Department of Internal Medicine V, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Crysandt M; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, Center for Integrated Oncology Aachen, Bonn Cologne Duesseldorf, Aachen, Germany., Jäger P; University Hospital of Düsseldorf, Düsseldorf, Germany., Krause SW; Department of Internal Medicine V, University Hospital Erlangen, Erlangen, Germany., Dierks C; University Hospital Halle, Halle, Germany., Klein S; University Medical Centre Mannheim, Mannheim, Germany., Maguire N; Barmherzige Brüder Hospital, Regensburg, Germany., Frenzel LP; Department I of Internal Medicine, Faculty of Medicine and Cologne University Hospital, Center for Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Düsseldorf, Cologne, Germany., Bücklein VL; LMU Hospital, Munich, Germany., Blau W; Department of Internal Medicine III, Hematology, Oncology and Palliative Care, Helios Dr. Horst Schmidt Hospital Wiesbaden, Wiesbaden, Germany., Kaiser U; Department of Hematology, Oncology and Immunology, St. Bernward Hospital, Hildesheim, Germany., Wegehenkel K; University Hospital OWL/Bielefeld Hospital, Bielefeld, Germany., Höllein A; Department of Internal Medicine III, Hematology and Oncology, Rotkreuzklinikum München, Munich, Germany., Seggewiss-Bernhardt R; Department of Internal Medicine V, Sozialstiftung Bamberg, Bamberg, Germany.; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany., Markgraf W; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Fiebig F; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Harig A; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Schmidt-Brücken K; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Thiede C; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany.; AgenDix GmbH, Dresden, Germany., Middeke JM; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Dillon R; King's College, London, UK., Baldus CD; Department of Hematology and Oncology, University Hospital Schleswig- Holstein, Campus Kiel, Kiel, Germany., Serve H; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Spiekermann K; LMU Hospital, Munich, Germany., Hiddemann W; LMU Hospital, Munich, Germany., Schlenk RF; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Müller-Tidow C; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Bornhäuser M; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany., Röllig C; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany. |
| Source: | Annals of hematology [Ann Hematol] 2025 Jul; Vol. 104 (7), pp. 3647-3654. Date of Electronic Publication: 2025 Jul 09. |
| Publication Type: | Journal Article; Clinical Trial Protocol |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-025-06496-7 |
